$6.83
8.08% today
Nasdaq, Apr 04, 09:17 pm CET
ISIN
US0887861088
Symbol
BCYC
Sector
Industry

Bicycle Therapeutics Plc Stock price

$7.43
-3.04 29.04% 1M
-14.77 66.53% 6M
-6.57 46.93% YTD
-15.89 68.14% 1Y
-37.72 83.54% 3Y
-6.03 44.80% 5Y
-6.57 46.93% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.62 7.70%
ISIN
US0887861088
Symbol
BCYC
Sector
Industry

Key metrics

Market capitalization $513.13m
Enterprise Value $-356.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 2.15
EV/Sales (TTM) EV/Sales -10.12
P/S ratio (TTM) P/S ratio 14.55
P/B ratio (TTM) P/B ratio 0.65
Revenue growth (TTM) Revenue growth 30.27%
Revenue (TTM) Revenue $35.27m
EBIT (operating result TTM) EBIT $-252.40m
Free Cash Flow (TTM) Free Cash Flow $-166.03m
Cash position $879.52m
EPS (TTM) EPS $-2.88
P/E forward negative
P/S forward 15.71
EV/Sales forward negative
Short interest 9.94%
Show more

Is Bicycle Therapeutics Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Bicycle Therapeutics Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Bicycle Therapeutics Plc forecast:

12x Buy
80%
3x Hold
20%

Analyst Opinions

15 Analysts have issued a Bicycle Therapeutics Plc forecast:

Buy
80%
Hold
20%

Financial data from Bicycle Therapeutics Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
35 35
30% 30%
100%
- Direct Costs 7.18 7.18
9% 9%
20%
28 28
37% 37%
80%
- Selling and Administrative Expenses 57 57
22% 22%
162%
- Research and Development Expense 216 216
19% 19%
613%
-245 -245
18% 18%
-695%
- Depreciation and Amortization 7.18 7.18
9% 9%
20%
EBIT (Operating Income) EBIT -252 -252
18% 18%
-716%
Net Profit -169 -169
7% 7%
-479%

In millions USD.

Don't miss a Thing! We will send you all news about Bicycle Therapeutics Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bicycle Therapeutics Plc Stock News

Neutral
Business Wire
2 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducemen...
Neutral
Business Wire
3 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m. ET...
Neutral
Business Wire
8 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced several new governance and key clinical leadership appointments. Felix J. Baker, Ph.D., will succeed Pierre Legault, BAA, MBA, CPA, CA, as chairma...
More Bicycle Therapeutics Plc News

Company Profile

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Kevin Lee
Employees 305
Founded 2009
Website bicycletherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today